Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients | Zendy

Noopur Raje | Zendy; Yee | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Author(s) -

Noopur Raje,

Yee

Publication year - 2012

Publication title -

clinical interventions in aging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.184

H-Index - 76

eISSN - 1178-1998

pISSN - 1176-9092

DOI - 10.2147/cia.s14566

Subject(s) - denosumab , medicine , zoledronic acid , prostate cancer , breast cancer , oncology , cancer , osteoporosis , osteoclast , bone disease , bone mineral , receptor

Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand. It is effective in settings ranging from preventing skeletal-related complications in cancer patients with metastatic disease to increasing bone mineral density in patients with osteoporosis. In cancer patients with early stage disease, denosumab can attenuate bone loss from antihormonal treatments, and in prostate cancer, may reduce disease progression. Here, we will discuss the important role denosumab may play in the management of bone loss in patients with cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research